[Pharmacological and clinical properties of AIMIX® combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate]

Nihon Yakurigaku Zasshi. 2013 Jul;142(1):39-46. doi: 10.1254/fpj.142.39.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Amlodipine / administration & dosage
  • Amlodipine / pharmacology*
  • Amlodipine / therapeutic use*
  • Angiotensin II Type 1 Receptor Blockers / administration & dosage
  • Angiotensin II Type 1 Receptor Blockers / pharmacology*
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use*
  • Animals
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / pharmacology*
  • Antihypertensive Agents / therapeutic use*
  • Biphenyl Compounds / administration & dosage
  • Biphenyl Compounds / pharmacology*
  • Biphenyl Compounds / therapeutic use*
  • Calcium Channel Blockers / administration & dosage
  • Calcium Channel Blockers / pharmacology*
  • Calcium Channel Blockers / therapeutic use*
  • Clinical Trials, Phase II as Topic
  • Drug Combinations
  • Drug Design
  • Humans
  • Hypertension / drug therapy*
  • Hypertension / etiology
  • Hypertension / physiopathology
  • Irbesartan
  • Tablets
  • Tetrazoles / administration & dosage
  • Tetrazoles / pharmacology*
  • Tetrazoles / therapeutic use*
  • Treatment Outcome

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents
  • Biphenyl Compounds
  • Calcium Channel Blockers
  • Drug Combinations
  • Tablets
  • Tetrazoles
  • Amlodipine
  • Irbesartan